Total Funding
53
96
Total FundingSeries C raised
Growth Score
-11 pts
Heat Score
35 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
942
Memo Therapeutics is a biotechnology research company that engages in antibody discovery and immune repertoire analysis.
Erik Berg: Chief Executive Officer
About the Company
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB platform creates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire
and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.
MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
